15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $17.3B | $1.4B | 51.8% | 12.5% | $1.1B | — | $3.6B |
| 2024 | $16.5B | -$1.6B | 48.7% | -1.8% | $749M | — | $3.3B |
| 2023 | $15.8B | -$559M | 48.2% | 2.7% | $842M | — | $3.2B |
| 2022 | $14.9B | -$2.4B | 46.7% | -14.7% | $1.0B | — | $2.8B |
| 2021 | $15.9B | $417M | 47.8% | 10.8% | $236M | — | $2.2B |
| 2020 | $16.7B | -$4.0B | 46.4% | -21.4% | — | — | $2.2B |
| 2019 | $16.9B | -$999M | 44.6% | -2.6% | — | — | $2.0B |
| 2018 | $18.3B | -$2.1B | 45.4% | -9.0% | — | — | $1.8B |
| 2017 | $21.9B | -$16.3B | 48.6% | -80.0% | — | $28.8B | $963M |
| 2016 | $21.9B | $329M | 53.2% | 9.8% | — | $32.5B | $988M |
| 2015 | — | $1.6B | — | — | — | $8.4B | $6.9B |
| 2014 | — | $3.1B | — | — | — | $8.6B | $2.2B |
| 2013 | — | $1.3B | — | — | — | $11.2B | $1.0B |
| 2012 | — | $2.0B | — | — | — | $14.1B | $2.9B |
| 2011 | — | $2.8B | — | — | — | $11.4B | $1.1B |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $4.0B | $369M | 49.5% | 16.4% | -$208M | — | $3.7B |
| Dec '25 | $4.7B | $480M | 56.4% | 6.4% | $1.0B | — | $3.6B |
| Sep '25 | $4.5B | $433M | 51.4% | 19.7% | $233M | — | $2.2B |
| Jun '25 | $4.2B | $282M | 50.3% | 10.9% | $131M | — | $2.2B |
| Mar '25 | $3.9B | $214M | 48.2% | 13.3% | -$232M | — | $1.7B |
| Dec '24 | $4.2B | -$217M | 50.2% | -0.7% | $446M | — | $3.3B |
| Sep '24 | $4.3B | -$437M | 49.6% | -1.2% | $545M | — | $3.3B |
| Jun '24 | $4.2B | -$846M | 48.6% | -0.1% | $6M | — | $2.3B |
| Mar '24 | $3.8B | -$139M | 46.4% | -5.7% | -$248M | — | $3.0B |
| Dec '23 | $4.5B | $463M | 54.2% | 17.0% | $1.1B | — | $3.2B |
| Sep '23 | $3.9B | $69M | 48.1% | 8.9% | -$144M | — | $2.2B |
| Jun '23 | $3.9B | -$872M | 46.3% | -16.9% | $205M | — | $2.7B |
| Mar '23 | $3.7B | -$220M | 43.2% | -0.4% | -$284M | — | $2.1B |
| Dec '22 | $3.9B | -$1.3B | 45.6% | -24.2% | $831M | — | $2.8B |
| Sep '22 | $3.6B | $61M | 46.4% | 11.8% | $421M | — | $2.2B |
| Jun '22 | $3.8B | -$251M | 47.4% | -25.5% | — | — | $2.1B |
| Mar '22 | $3.7B | -$955M | 47.5% | -19.5% | — | — | $2.2B |
| Dec '21 | $4.1B | -$159M | 50.0% | 1.9% | — | — | $2.2B |
| Sep '21 | $3.9B | $292M | 46.2% | 16.0% | — | — | $2.0B |
| Jun '21 | $3.9B | $207M | 47.9% | 14.9% | — | — | $2.4B |
How the market has priced TEVA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Teva Pharmaceutical Industries Ltd's revenue has grown 0.7% per year. These are computed facts, not advice.
As of FY2025, Teva Pharmaceutical Industries Ltd reported — of total debt against $3.6B of cash; operating income covered interest expense 2.4×.
In FY2025, gross margin was 51.8%, operating margin 12.5%, and net margin 8.2%.
As of Jun '26, Teva Pharmaceutical Industries Ltd traded at a price-to-earnings ratio of about 27.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.